User profiles for Rachel Thijssen
 | Rachel ThijssenAssistant Professor, Amsterdam UMC Verified email at wehi.edu.au Cited by 2328 |
Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
P Blombery, MA Anderson, J Gong, R Thijssen… - Cancer discovery, 2019 - AACR
Why CLL recurs in patients who achieve remission with the BCL2 inhibitor venetoclax has
been unknown. We provide the first description of an acquired point mutation in BCL2 arising …
been unknown. We provide the first description of an acquired point mutation in BCL2 arising …
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
R Thijssen, ST Diepstraten, D Moujalled… - Blood, The Journal …, 2021 - ashpublications.org
Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative
treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-…
treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-…
[HTML][HTML] Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing
A modified Chromium 10x droplet-based protocol that subsamples cells for both short-read
and long-read (nanopore) sequencing together with a new computational pipeline (FLAMES) …
and long-read (nanopore) sequencing together with a new computational pipeline (FLAMES) …
[HTML][HTML] Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
…, G Lessene, IJ Majewski, R Thijssen… - Nature …, 2019 - nature.com
Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery
promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with …
promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with …
Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
Ibrutinib plus venetoclax is a highly effective combination in mantle cell lymphoma. However,
strategies to enable the evaluation of therapeutic response are required. Our prospective …
strategies to enable the evaluation of therapeutic response are required. Our prospective …
IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells
…, EBM Remmerswaal, R Thijssen… - Blood, The Journal …, 2013 - ashpublications.org
Chronic lymphocytic leukemia (CLL) cells multiply in secondary lymphoid tissue, but the
mechanisms leading to their proliferation are still uncertain. In addition to B-cell receptor (BCR)–…
mechanisms leading to their proliferation are still uncertain. In addition to B-cell receptor (BCR)–…
[HTML][HTML] Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
R Thijssen, E Slinger, K Weller, CR Geest… - …, 2015 - ncbi.nlm.nih.gov
A major clinical problem in chronic lymphocytic leukemia (CLL) is development of
chemoresistance, which can be caused by genetic lesions but is also strongly influenced by the …
chemoresistance, which can be caused by genetic lesions but is also strongly influenced by the …
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
…, J Gong, X Chen, M McBean, R Thijssen… - Blood, The Journal …, 2020 - ashpublications.org
The BCL2 inhibitor venetoclax has complete response rates of up to 50% in chronic lymphocytic
leukemia patients, but secondary resistance reflecting acquired mutations in BCL2 can …
leukemia patients, but secondary resistance reflecting acquired mutations in BCL2 can …
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
R Thijssen, L Tian, MA Anderson… - Blood, The Journal …, 2022 - ashpublications.org
Venetoclax (VEN) inhibits the prosurvival protein BCL2 to induce apoptosis and is a standard
therapy for chronic lymphocytic leukemia (CLL), delivering high complete remission rates …
therapy for chronic lymphocytic leukemia (CLL), delivering high complete remission rates …
[HTML][HTML] Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
M Haselager, R Thijssen, C West, L Young… - Cell Death & …, 2021 - nature.com
In chronic lymphocytic leukemia (CLL), the lymph node (LN) microenvironment delivers critical
survival signals by inducing the expression of anti-apoptotic Bcl-2 members Bcl-XL, Bfl-1, …
survival signals by inducing the expression of anti-apoptotic Bcl-2 members Bcl-XL, Bfl-1, …